Organon partners with Huya to identify and develop Chinese biopharmaceuticals
Collaboration looks for opportunities to expand the Organon biotech research programs and facilitate links with China's biotech industry
Organon announced that it has signed a collaboration agreement with HUYA Bioscience International, LLC, (HUYA) to search for new, proprietary biopharmaceuticals or pharmaceutical compounds. As part of this collaboration, Organon has acquired an equity interest in HUYA.
HUYA, with offices in San Diego and Shanghai, identifies, licenses and develops Chinese drug candidates for commercialization in Western markets. Under the collaboration agreement, HUYA will support Organon in the sourcing and development of pharmaceutical or biopharmaceutical compounds in three specific therapeutic areas.
No financial details of the transaction were disclosed.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.